June 6, 2022Open Access

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Rucaparib monotherapy is effective as first-line maintenance, conferring significant benefit versus placebo in patients with advanced ovarian cancer with and without HRD.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Bradley J. Monk

Florida Cancer Specialists & Research Institute

Christine Parkinson

National Health Service

Myong Cheol Lim

Gynecologic Oncology Group

Journals

Journal of Clinical Oncology

Actions

Institutions

Harvard University

Massachusetts General Hospital

Imperial College London

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

Puntos clave

Resumen

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study